An investment firm that administers four evergreen life science investment funds is making investments in both privately held and publicly traded life science companies. In general the funds can only invest in US-based companies. The firm makes an average of 4 new early stage life science investments each year, and initial investments are typically $6-10m initially with the potential for further investment in follow-on rounds. The firm invests at a wide range of developmental stages, typically from Series B through to IPOs and PIPEs.
The funds are extremely opportunistic within the life science sector, and consider opportunities in drug development, medical devices and healthcare IT. The funds prefers to invest in companies with clinical data but will also consider preclinical opportunities.
The funds invest in both privately held and publicly traded companies. The firm only invests in management teams that have relevant industry experience, preferring not to work with new entrepreneurs.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com
Next Phase Newsletter 
Leave a comment